PRESS RELEASE published on 03/23/2026 at 07:30, 3 months 4 days ago Just – Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses Just - Evotec Biologics partners with BARDA to optimize biomanufacturing of antibodies against Ebola & related viruses, strengthening U.S. government response capabilities Just - Evotec Biologics BARDA Biomanufacturing Ebola Antibodies
BRIEF published on 03/19/2026 at 07:35, 3 months 8 days ago Evotec Achieves $10M Milestone in Collaboration with Bristol Myers Squibb Cancer Treatment Clinical Trial Evotec Bristol Myers Squibb Molecular Glues
BRIEF published on 03/19/2026 at 07:35, 3 months 8 days ago Evotec franchit le cap des 10 millions de dollars de collaboration avec Bristol Myers Squibb Essai Clinique Traitement Du Cancer Evotec Bristol Myers Squibb Colles Moléculaires
PRESS RELEASE published on 03/19/2026 at 07:30, 3 months 8 days ago Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation Evotec receives $10 M milestone from Bristol Myers Squibb for Phase 1 clinical study initiation of BMS-986506 in clear cell renal cell carcinoma. Collaboration focuses on protein degradation for cancer treatment Oncology Clinical Study Evotec Bristol Myers Squibb Protein Degradation
BRIEF published on 03/10/2026 at 07:35, 3 months 17 days ago Evotec Unveils 'Horizon' Strategy for Growth and Agility Drug Discovery Transformation Evotec Scientific Leadership Horizon Strategy
BRIEF published on 03/10/2026 at 07:35, 3 months 17 days ago Evotec dévoile sa stratégie « Horizon » pour la croissance et l'agilité Transformation Evotec Découverte De Médicaments Leadership Scientifique Stratégie Horizon
PRESS RELEASE published on 03/10/2026 at 07:30, 3 months 17 days ago Evotec Announces ‘Horizon’ – Next Inflection in Its Strategic Transformation to Accelerate Growth and Promote Agility Evotec SE announces 'Horizon', the next phase in its strategic transformation to accelerate growth and promote agility through a new operating model across operations, science, and commercial execution Evotec SE Growth Strategic Transformation Horizon Operating Model
BRIEF published on 01/08/2026 at 07:35, 5 months 19 days ago Just – Evotec Biologics Secures Grant for AI in Monoclonal Antibody Development Evotec SE AI Optimization Monoclonal Antibodies Gates Foundation J.DESIGN™ Platform
BRIEF published on 01/08/2026 at 07:35, 5 months 19 days ago Evotec Biologics obtient une subvention pour l'IA dans le développement d'anticorps monoclonaux Evotec SE Anticorps Monoclonaux Fondation Gates Optimisation Par IA Plateforme J.DESIGN™
PRESS RELEASE published on 01/08/2026 at 07:30, 5 months 19 days ago Just – Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access Just - Evotec Biologics, a subsidiary of Evotec SE, receives grant from Gates Foundation to optimize monoclonal antibody development using AI-driven molecular design, enhancing affordability and global access Evotec SE Grant Just - Evotec Biologics Gates Foundation Monoclonal Antibody
Published on 06/27/2026 at 01:40, 12 hours 14 minutes ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 13 hours 54 minutes ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 14 hours 54 minutes ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 15 hours 4 minutes ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/26/2026 at 22:15, 15 hours 39 minutes ago Revive Therapeutics Announces Proposed Private Placement
Published on 06/27/2026 at 00:05, 13 hours 49 minutes ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 13 hours 50 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 14 hours 18 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 14 hours 18 minutes ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 14 hours 26 minutes ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE